AOD-9604 vs HGH Fragment 176-191: GH-Derived Fat-Loss Peptides

AOD-9604 and HGH Fragment 176-191 are two synthetic peptides derived from the C-terminal region of human growth hormone, developed to isolate the lipolytic properties of full-length GH without its anabolic or glucoregulatory activity. Both compounds have been studied in preclinical and early clinical settings as tools for investigating adipose tissue metabolism, yet they differ in their structural origin stories, regulatory histories, and the breadth of research conducted. Understanding these distinctions requires examining the science behind how each was designed, what the published literature has found, and how they are currently classified by regulatory and anti-doping authorities.

This article summarizes published preclinical and clinical research on both compounds. It is intended as a research reference, not a clinical recommendation.

Research reference only. All information on this page is a summary of peer-reviewed scientific literature and does not constitute medical advice. See individual library profiles for full compound data.

AOD-9604: Mechanism and evidence base

AOD-9604 (Anti-Obesity Drug 9604) is a synthetic peptide corresponding to residues 177-191 of human growth hormone, with an additional tyrosine added at the N-terminus to stabilize the fragment and improve bioavailability. The compound was developed by Metabolic Pharmaceuticals (now Calzada Ltd.) specifically to replicate the fat-metabolizing effect of GH without the receptor-binding regions responsible for IGF-1 induction, linear growth, or insulin antagonism.

Mechanistically, AOD-9604 is understood to act on adipocyte beta-3 adrenergic receptors rather than the canonical growth hormone receptor (GHR). This binding activates intracellular cAMP cascades that upregulate hormone-sensitive lipase (HSL) activity, promoting the hydrolysis of stored triglycerides (lipolysis), while simultaneously suppressing lipogenesis through downregulation of fatty acid synthase (FAS) activity. Crucially, the sequence modifications that produce this activity also eliminate the binding affinity for the GHR Ig-like domain, which is the structural feature responsible for IGF-1 secretion and hyperglycemic effects in full-length GH.

Preclinical studies in obese mouse and rat models reported significant reductions in adipose tissue mass following AOD-9604 administration, with no measurable changes in blood glucose, serum IGF-1, or body lean mass. These early animal studies used both subcutaneous and oral administration routes, with subcutaneous delivery demonstrating greater bioavailability in pharmacokinetic assessments. Oral formulations were also explored given the compound's small size relative to full-length GH, which cannot survive gastrointestinal proteolysis. A study published in Obesity Research demonstrated dose-dependent lipolytic activity in obese Zucker rats with a superior safety profile compared to full-length GH. AOD-9604 subsequently advanced to human Phase II trials. A Phase IIb randomized controlled trial (the METRO trial) enrolled approximately 300 overweight subjects across multiple doses. While the treatment groups demonstrated trends toward weight reduction, the primary endpoint — body weight change at 24 weeks — did not achieve statistical significance at any dose compared to placebo, and Metabolic Pharmaceuticals discontinued further development for an obesity indication. The compound is classified as Investigational by the FDA and is listed as a prohibited substance by the World Anti-Doping Agency (WADA) under the category of peptide hormones and related substances (PMID 26578461 — "Simplifying and expanding the screening for peptides <2 kDa by direct urine injection," Drug Testing and Analysis, 2016).

HGH Fragment 176-191: Mechanism and evidence base

HGH Fragment 176-191 is a synthetic peptide corresponding to the 16 C-terminal amino acids of human growth hormone (residues 176-191), without the additional N-terminal tyrosine that distinguishes AOD-9604. The fragment was first characterized in a landmark structural study demonstrating that the lipolytic activity of full-length GH resides primarily in this C-terminal region. The research, published in the Journal of Molecular Biology, confirmed that the fragment retains the ability to stimulate lipolysis and inhibit lipogenesis through a receptor interaction that is structurally distinct from the canonical two-site GHR-binding mechanism (PMID 11713473 — "Lipolytic activity of the carboxyl-terminal fragment of human growth hormone," J Mol Biol, 2001; DOI https://doi.org/10.1006/jmbi.2001.5070).

HGH Fragment 176-191's proposed mechanism involves binding to a distinct adipocyte receptor that couples to adenylate cyclase, activating the same downstream lipolytic cascade as GH without engaging IGF-1-producing hepatic pathways. In preclinical models, the fragment stimulated fat breakdown in adipose tissue depots while sparing lean mass and failing to produce measurable changes in serum IGF-1, blood glucose, or growth plate activity, indicating that the fragment selectively accesses the metabolic rather than the anabolic arm of GH signaling.

Unlike AOD-9604, HGH Fragment 176-191 has not advanced to published Phase II efficacy trials and is classified as a preclinical compound. It is also included on the WADA 2026 Prohibited List as a GH fragment, restricting its use in competitive sport research contexts. Researchers studying this fragment note that the published clinical pharmacology data are limited and that most evidence base comes from rodent models, representing a meaningful gap relative to AOD-9604's more developed (though ultimately inconclusive) human clinical record.

Side-by-side comparison

Differential research applications

Published protocols distinguish between the two compounds primarily based on their development history rather than any demonstrated mechanistic superiority. AOD-9604's advancement through human Phase II trials provides a more extensive safety database and established pharmacokinetic parameters in humans, making it the more cited compound in clinical metabolism research. Studies examining the relationship between GH-derived peptides and adipocyte lipolysis signaling generally reference AOD-9604 data when seeking translationally relevant findings.

HGH Fragment 176-191, in contrast, is more frequently cited in structural biochemistry and receptor pharmacology research contexts, where investigators are studying the structural basis of GH's metabolic versus anabolic functions. The native fragment is the foundational compound that established the principle of functional dissociation within GH structure; AOD-9604 represents a subsequent pharmaceutical optimization of that insight.

Researchers studying lipogenesis inhibition mechanisms have used both compounds in parallel to probe the relative contributions of sequence-specific binding interactions. Where investigators require a human-trialed compound with documented safety data for context, AOD-9604 is preferred. Where mechanistic binding studies focused on native GH fragment interactions are the goal, HGH Fragment 176-191 serves as the primary research tool.

One important research consideration is that neither compound has demonstrated statistically significant fat-loss effects in controlled human trials, and the inference from animal models to human outcomes for this class of fragment has not been confirmed. This limits the translational conclusions that can be drawn from preclinical studies using either compound.

The broader research value of both compounds lies in what they have revealed about GH receptor pharmacology: the demonstration that lipolytic and anabolic activities of growth hormone can be structurally dissociated has informed the design of subsequent GH analogs, fragment-based pharmaceuticals, and adipocyte signaling studies. Investigators examining adipocyte lipase regulation, triglyceride metabolism, or GH receptor structure-activity relationships continue to reference the foundational HGH Fragment 176-191 characterization studies alongside the more recent clinical pharmacology data generated in AOD-9604 trials. This layered citation pattern reflects the compounds' complementary roles: one as a structural proof of principle, the other as a pharmacologically optimized and clinically investigated derivative.

Regulatory and compounding status

Both compounds are classified by the FDA as lacking approved indications. AOD-9604 was investigated for an obesity indication under IND status and completed Phase IIb without achieving its primary endpoint; no NDA has been filed. HGH Fragment 176-191 has not been the subject of an IND application for an efficacy indication.

Under the 503A compounding framework, both compounds are listed as Under Review, meaning their status as bulk drug substances eligible for patient-specific compounding is subject to ongoing FDA evaluation and neither has been placed on a positive list permitting routine compounding.

The WADA 2026 Prohibited List includes both compounds under Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). AOD-9604 is explicitly named as a prohibited GH-releasing peptide analog, while HGH Fragment 176-191 falls under the broader prohibition covering GH fragments and releasing factors. This classification applies regardless of purpose and is relevant to researchers publishing findings in sport science or anti-doping contexts.

Neither compound is approved by the European Medicines Agency (EMA) for any indication.

Cited studies

• PMID 26578461 — "Simplifying and expanding the screening for peptides <2 kDa by direct urine injection, liquid chromatography, and ion mobility mass spectrometry." Drug Testing and Analysis, 2016. DOI: https://doi.org/10.1517/13543776.11.1.113
• PMID 11713473 — "Lipolytic activity of the carboxyl-terminal fragment of human growth hormone." Journal of Molecular Biology, 2001. DOI: https://doi.org/10.1006/jmbi.2001.5070

For full compound profiles, see the library entries for AOD-9604 and HGH Fragment 176-191.

For laboratory research purposes only. Not for human or animal consumption. Compounds described are not approved by the FDA for human or veterinary use unless explicitly stated.